An update from Armata Pharmaceuticals ( (ARMP) ) is now available.
Armata Pharmaceuticals has announced the full enrollment of its Phase 1b/2a diSArm study, evaluating the intravenous AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia, a severe bloodstream infection. With results expected in early 2025, the study aims to address the growing resistance to antibiotics, offering hope for innovative bacteriophage therapies in combating challenging infections. The upcoming data could pave the way for a pivotal efficacy trial later in the year, marking a significant step in modern medicine’s fight against antibiotic-resistant pathogens.
See more insights into ARMP stock on TipRanks’ Stock Analysis page.
